TTTorgrim Tandstad

Torgrim Tandstad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Torgrim Tandstad has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Anders Kjellman

    Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institute, Stockholm, Sweden; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden

    2 shared publications
  • Anna Grenabo Bergdahl

    Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Region Västra Götaland, Sahlgrenska University Hospital, Department of Urology, Gothenburg, Sweden

    2 shared publications
  • Anna Thor

    Division of Urology, Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden

    2 shared publications
  • Gabriella Cohn-Cedermark

    Department of Oncology - Pathology, Karolinska Institute, Stockholm, Sweden; Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Stockholm, Sweden

    2 shared publications
  • Harald Kåre Engan

    Unicare Rehabilitation Norway, 0609 Oslo, Norway

    2 shared publications
  • Per-Olof Lundgren

    Department of Clinical Science, Technology and Intervention Karolinska Institute Stockholm Sweden

    2 shared publications

Latest Publications

  • Open Access

    Development of CaReScreen, a Digital Health Tool for Assessing Late Effects and Cancer Rehabilitation Needs in Cancer Survivors: Protocol for a Qualitative Development and Formative Design Study

    by Maja Kulosman, Harald Kåre Engan, Unn Merete Fagerli, Kristin Valborg Reinertsen, Kari Sand, Jon Arne Sandmæl, Arne Solberg, Torgrim Tandstad

    Background: Due to advances in cancer diagnostics and treatments, life expectancy after cancer and the number of cancer survivors are increasing. Symptoms and late effects frequently occur in cancer survivors, with a negative impact on functioning and participation in society. Digital health tools might be helpful to systematically assess symptom burden of late effects and rehabilitation needs. Objective: This paper describes the objectives, design, and current status of the Cancer Rehabilitation Screening (CaReScreen) project. The aims are (1) to report the completed development phase of the digital health tool CaReScreen, comprising the exploratory work, the establishment of the interdisciplinary team, the selection of the assessment instrument, and the development of the initial prototype, and (2) to define the objectives, design, and timelines of the ongoing validation of the scoring manual and of the planned large-scale feasibility study. Methods: Development followed an iterative, qualitative, and participatory design approach guided by established frameworks for digital health development. It was informed by exploratory qualitative work comprising 40 interviews (9 group and 31 individual) involving 72 informants across Norway, which identified systematic assessment of late effects and navigation of rehabilitation services as the primary unmet needs in cancer survivorship follow-up. A 105-item patient-reported outcome measure (European Organization for Research and Treatment of Cancer [EORTC] QLQ-SURV100, supplemented with 5 EORTC QLQ-C30 items) was selected as the main assessment instrument. This paper reports the completed development phase; the ongoing validation study and the planned feasibility study are described in terms of objectives, design, and timelines, but their results are not reported here. Results: An initial prototype was developed with health care professionals and cancer survivors as intended end users. It consists of a digital report that identifies and graphically visualizes a panoramic view of multidimensional needs, based on a traffic light scoring system: green indicates low symptom burden and high functioning, yellow moderate symptom burden and moderate functioning, and red high symptom burden and low functioning. The project is funded for the period 2022 to 2028. The development phase is completed, as well as early prototype usability and usefulness testing. Validation of the scoring manual is ongoing, with 800 participants included to date and reporting expected in spring 2027. A large-scale feasibility study is planned to commence in 2027. Conclusions: The CaReScreen interdisciplinary team has developed an initial digital health tool prototype with the main aim of enabling systematic assessment of late effects, functioning, and unmet rehabilitation needs in cancer survivors. The prototype now proceeds to validation and feasibility testing, which will determine its clinical utility and support regulatory approval under the European Medical Device Regulation.

  • Open Access

    Complications and clinical outcomes of retroperitoneal lymph node dissection for testicular cancer in a centralized population-based cohort in Sweden: insights from SWENOTECA

    by Anna Thor, Anna Grenabo Bergdahl, Armin Abniki, Axel Gerdtsson, Ingrid Glimelius, Martin Hellström, Anna K. Jansson, Berglind Johannsdottir, Torgrim Tandstad, Gabriella Cohn-Cedermark, et al.

    Objective: Retroperitoneal lymph node dissection (RPLND) for testicular germ cell cancer is a complex procedure associated with postoperative complications and long-term morbidity, best performed by experienced surgeons at high-volume centers. This study evaluates surgical outcomes of RPLND in a centralized population-based cohort. Methods: This is a retrospective analysis of a prospective multicenter cohort of all RPLNDs in Sweden between 2018 and 2022. 217 patients (175 nonseminomas and 42 seminomas) underwent unilateral or bilateral primary RPLND or post-chemotherapy RPLND. Primary outcomes were complications, loss of ejaculation, and histopathology. Results: Intraoperative complications occurred in 8% of unilateral and 0% of bilateral templates in primary RPLND, and in 0 and 8% in post-chemotherapy RPLND, most commonly renal injury. Postoperative complications rate was significantly higher with bilateral templates in post-chemotherapy RPLND (49% vs 18%, p < 0.01). Clavien-Dindo ≥ IIIb complications occurred in 2 (primary) and 3% (post-chemotherapy), respectively. Loss of ejaculation was numerically more common after bilateral templates (primary: 60% vs 31%, p = 0.07; post-chemotherapy: 53% vs 38%, p = 0.09). Viable cancer was found in 95% of seminomas and 52% of nonseminomas for primary RPLND and in nonseminoma post-chemotherapy RPLND, 11% viable cancer, 50% teratoma, and 39% benign nodes. Robotic surgery did not increase complications or loss of ejaculation. Conclusions: RPLND demonstrated low complication rates and rare serious events. Bilateral templates were associated with increased loss of ejaculation. Robotic surgery was safe, and prior chemotherapy did not preclude laparoscopy. Post-chemotherapy RPLND showed more teratoma and viable cancer, and fewer benign findings than previously reported.

  • Open Access

    Breast cancer and long-term employment: A retrospective cohort study from Norway

    by Roy A. Nielsen, Eliva Atieno Ambugo, Steffen Torp, Torgrim Tandstad, Guro Birgitte Stene, Line Oldervoll, Alain Paraponaris, Harald K. Engan

    Background: Breast cancer and its treatment may contribute to an increased risk of unemployment, influenced by both disease-related factors and socioeconomic determinant. Few longitudinal studies have examined employment outcomes among women diagnosed with cancer. This retrospective study investigated long-term employment among breast cancer survivors (BCS) and assessed disease specific and socioeconomic factors associated with employment. Design and methods: Registry-based data included working age BCS in Norway 2004–2008 alive at 6 years follow-up ( N = 3560). The employment status on each BCS was compared to two matched non-cancer controls ( N = 7081) by means of logistic regression analyses with marginal effects. Separate analyses by employment status at the time of diagnosis were conducted. Results: Among BCS employed at diagnosis, 73.7%, 71.5% and 71.8% of BCS were in employment at 1, 2 and 6 years after diagnosis, respectively. BCS employed at diagnosis had significantly lower probability of being employed at all follow-up time points, compared to controls. BCS outside employment at the time of diagnosis experienced lower probability of employment compared to controls. BCS with secondary or higher education had higher probability of employment compared to BCS with basic education, and BCS living in families with children were more likely to enter employment during follow-up compared to BCS without children. Conclusions: BCS employed at diagnosis had a subsequent risk of unemployment, and BCS not employed at diagnosis had lower probability of entering employment. Additional risk factors are high age, low education, and being single without children. Significance for public health: The risk of unemployment after a breast cancer diagnosis was increased. Job loss is costly economically and socially, both for individuals and for society. Early focus on employment particularly among employees with low education and with little family support may alleviate this problem.

  • Open Access

    miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study

    by Anna Thor, Mette Pernille Myklebust, Anna Grenabo Bergdahl, Per-Olof Lundgren, Viktor Skokic, Bjarte Almås, Hege Sagstuen Haugnes, Torgrim Tandstad, Olof Akre, Gabriella Cohn-Cedermark, et al.

    The SWENOTECA-MIR prospective multicenter study aims to assess the clinical value of miR-371a-3p as a novel marker in metastatic germ cell tumor patients undergoing retroperitoneal lymph node dissection (RPLND), to predict the presence of viable residual tumor. A total of 114 patients (86 nonseminomas, 28 seminomas) who underwent surgery for presumed metastatic disease pre-chemotherapy (primary RPLND), and post-chemotherapy RPLND were included. The expression of miR-371a-3p was evaluated using RT-digital droplet PCR before and after RPLND. Pre- and post-operative miR-371a-3p levels were statistically compared, and optimism-corrected performance calculations compared with conventional serum tumor markers. Associations were evaluated by logistic regression. Patients who underwent primary RPLND were categorized into seminoma and nonseminoma groups. Among the seminoma patients (n = 24) undergoing primary RPLND, all had normal conventional markers. Six patients received adjuvant treatment before surgery. miR-371a-3p exhibited a sensitivity of 74%, specificity of 100%, PPV of 100% and NPV of 21% for viable tumor. The levels of miR-371a-3p significantly decreased after surgery. In the nonseminoma group (n = 18) treated with primary RPLND, 22% had elevated conventional markers, and 3 had received prior adjuvant treatment. miR-371a-3p showed a sensitivity of 34%, specificity of 88%, PPV of 67% and NPV of 62% for the primary nonseminoma patients. No association was observed between stage or prior adjuvant treatment, and the outcome of the miR-test. In the post-chemotherapy group (n = 72), the miR-371a-3p sensitivity was 9%, reducing to 0 when excluding patients with seminoma (n = 4). Teratomas and benign histology were essentially negative. Our study highlights miR-371a-3p as a fairly sensitive and highly specific marker for pre-chemotherapy seminomas, outperforming conventional markers. However, in pre-chemotherapy non-seminomas as well as in post-chemotherapy patients, we observed low sensitivity and no significant differences in miR-371a-3p levels before and after surgery, suggesting limited utility for miR-371a-3p in this context.


  • Pneumonitis and fibrosis after breast cancer radiotherapy: occurrence and treatment-related predictors

    by Jarle Karlsen, Torgrim Tandstad, Piotr Sowa, Øyvind Salvesen, Jo S. Stenehjem, Steinar Lundgren, Randi J. Reidunsdatter

    Radiation pneumonitis (RP) and radiation fibrosis (RF) are common side effects after breast cancer (BC) radiotherapy (RT). However, there is a great variation in the frequency of RP and RF. This st...


  • Open Access

    Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953–2015: A population-based prospective cohort study

    by Øivind Kvammen, Tor Åge Myklebust, Arne Solberg, Bjørn Møller, Olbjørn Harald Klepp, Sophie Dorothea Fosså, Torgrim Tandstad

    Testicular germ cell tumor (TGCT) patients and survivors have excess mortality compared to the general male population, but relative survival (RS) has been scarcely studied. We investigated causes of excess mortality and their impact on RS among men diagnosed with TGCT in Norway, 1953–2015. Using registry data (n = 9541), standardized mortality ratios (SMRs) and RS were calculated. By December 31st, 2015, 816 testicular cancer (TC) and 1508 non-TC deaths had occurred (non-TC SMR: 1.36). Within five years of TGCT diagnosis, 80% were TC deaths. Non-TC second cancer (SC) caused 65% of excess non-TC deaths, of which 34% from gastric, pancreatic or bladder cancer. SC SMRs remained elevated ≥26 years of follow-up. In localized TGCT diagnosed >1979, SC SMRs were only elevated after seminoma. Cardiovascular disease caused 9% and other causes 26% of excess non-TC deaths, of which 58% from gastrointestinal and genitourinary disorders. RS continuously declined with follow-up. TGCT patients diagnosed >1989 had superior five-year TC-specific RS (98.3%), lower non-TC SMR (1.21), but elevated SMRs for several SCs, infections, Alzheimer’s disease, genitourinary disease and suicide. A limitation was lack of individual treatment data. RS declines mainly from TC deaths <5 years after TGCT diagnosis. Later, excess SC mortality becomes particularly important, reducing RS even ≥26 years. Radiotherapy; standard adjuvant seminoma treatment 1980–2007, is likely an important contributor, as are chemotherapy and possibly innate susceptibilities. Vigilant long-term follow-up, including psychosocial aspects, is important. Further research should focus on identifying survivor risk groups and optimizing treatment.